Abstract | UNLABELLED: METHODS: This prospective, Phase IV, randomized, blinded end point, active-controlled clinical trial will randomize 142 patients with chronic heart failure in New York Heart Association functional class II-IV to 8 months treatment with either torasemide-PR (10-40 mg daily) or furosemide (40-160 mg daily). The primary objective is to test the hypothesis that torasemide-PR is superior to furosemide in reducing myocardial fibrosis. The primary outcome measure is the difference in the change of serum propeptide of procollagen type I concentration from the initial to the final visit between both study groups. Secondary outcome measures include all efficacy variables related to heart failure (signs and symptoms, ECG, echocardiogram and serum levels of N-terminal brain natriuretic propeptide). Secondary safety variables are heart rate, blood pressure, laboratory data, adverse events, cardiovascular events (hospital admission, emergency department visits) and quality of life (Minnesota questionnaire). DISCUSSION: This trial will test whether torasemide-PR possesses antifibrotic properties, which may provide an additional benefit beyond diuresis in patients with chronic heart failure.
|
Authors | Javier Díez, Antonio Coca, Eduardo de Teresa, Manuel Anguita, Alfonso Castro-Beiras, Pedro Conthe, Erik Cobo, Ester Fernández, TORAFIC Investigators Group |
Journal | Expert review of cardiovascular therapy
(Expert Rev Cardiovasc Ther)
Vol. 7
Issue 8
Pg. 897-904
(Aug 2009)
ISSN: 1744-8344 [Electronic] England |
PMID | 19673667
(Publication Type: Clinical Trial, Phase IV, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Collagen Type I
- Delayed-Action Preparations
- Diuretics
- Peptide Fragments
- Procollagen
- Sulfonamides
- procollagen type I carboxy terminal peptide
- Furosemide
- Torsemide
|
Topics |
- Chronic Disease
- Collagen Type I
(blood)
- Delayed-Action Preparations
- Diuretics
(administration & dosage, therapeutic use)
- Female
- Fibrosis
(drug therapy, physiopathology)
- Furosemide
(administration & dosage, therapeutic use)
- Heart Failure
(drug therapy, physiopathology)
- Humans
- Male
- Peptide Fragments
(blood)
- Procollagen
(blood)
- Prospective Studies
- Research Design
- Sulfonamides
(administration & dosage, therapeutic use)
- Torsemide
|